BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37241915)

  • 1.
    Rajagopal K; Kalusalingam A; Bharathidasan AR; Sivaprakash A; Shanmugam K; Sundaramoorthy M; Byran G
    Molecules; 2023 May; 28(10):. PubMed ID: 37241915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-silico Design, ADMET Screening, MM-GBSA Binding Free Energy of Some Novel Isoxazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer.
    Kalirajan R; Pandiselvi A; Gowramma B; Balachandran P
    Curr Drug Res Rev; 2019; 11(2):118-128. PubMed ID: 31513003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Artonin E and Structural Analogs from Artocarpus Species Abrogates Estrogen Receptor Signaling in Breast Cancer.
    Etti I; Abdullah R; Hashim NM; Kadir A; Abdul AB; Etti C; Malami I; Waziri P; How CW
    Molecules; 2016 Jun; 21(7):. PubMed ID: 27367662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, and
    Choudhari RC; Kaur K; Das A; Jaitak V
    Curr Comput Aided Drug Des; 2024; 20(5):640-652. PubMed ID: 37888813
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Alamri A; Rauf A; Khalil AA; Alghamdi A; Alafnan A; Alshammari A; Alshammari F; Malik JA; Anwar S
    Biomed Res Int; 2021; 2021():9734279. PubMed ID: 34957309
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Maruthanila VL; Elancheran R; Mirunalini S
    Curr Comput Aided Drug Des; 2022; 18(3):196-212. PubMed ID: 35598239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer - An in-silico approach.
    Rajagopal K; Sri VB; Byran G; Gomathi S
    Curr Drug Res Rev; 2022; 14(1):61-72. PubMed ID: 34139975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico Molecular Modelling of Selected Natural Ligands and their Binding Features with Estrogen Receptor Alpha.
    Maruthanila VL; Elancheran R; Roy NK; Bhattacharya A; Kunnumakkara AB; Kabilan S; Kotoky J
    Curr Comput Aided Drug Des; 2019; 15(1):89-96. PubMed ID: 30306879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An
    Malkaje S; Srinivasa MG; Deshpande N S; Navada S; Revanasiddappa Bc
    Curr Drug Res Rev; 2023; 15(1):88-100. PubMed ID: 36017854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy.
    Yu E; Xu Y; Shi Y; Yu Q; Liu J; Xu L
    J Mol Model; 2019 Aug; 25(9):278. PubMed ID: 31463793
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Bouricha EM; Hakmi M; Akachar J; Zouaidia F; Ibrahimi A
    J Biomol Struct Dyn; 2022 Jul; 40(11):5203-5210. PubMed ID: 33402049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-silico Design, ADMET Screening, Prime MM-GBSA Binding Free Energy Calculation and MD Simulation of Some Novel Phenothiazines as 5HT6R Antagonists Targeting Alzheimer's Disease.
    V P; A M; N R
    Curr Comput Aided Drug Des; 2024 Jan; ():. PubMed ID: 38204222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Silico Elucidation of the Plausible Inhibitory Potential of Withaferin A of Withania Somnifera Medicinal Herb Against Breast Cancer Targeting Estrogen Receptor.
    Ali MA; Farah MA; Al-Anazi KM; Basha SH; Bai F; Lee J; Al-Hemaid FMA; Mahmoud AH; Hailan WAQ
    Curr Pharm Biotechnol; 2020; 21(9):842-851. PubMed ID: 31995002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational Study of the Binding Modes of Diverse DPN Analogues on Estrogen Receptors (ER) and the Biological Evaluation of a New Potential Antiestrogenic Ligand.
    Martinez-Archundia M; García-Vázquez JB; Colin-Astudillo B; Bello M; Prestegui-Martel B; Chavez-Blanco A; Dueñas-González A; Fragoso-Vázquez MJ; Mendieta-Wejebe J; Abarca-Rojano E; Ordaz-Rosado D; García-Becerra R; Castillo-Bautista D; Correa Basurto J
    Anticancer Agents Med Chem; 2018; 18(11):1508-1520. PubMed ID: 29189179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical Characterization,
    Ansari JA; Ahmad MK; Fatima N; Azad I; Mahdi AA; Satyanarayan GNV; Ahmad N
    Anticancer Agents Med Chem; 2022; 22(20):3416-3437. PubMed ID: 35125087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposing of approved drugs for targeting CDK4/6 and aromatase protein using molecular docking and molecular dynamics studies.
    Yousif FA; Alzain AA; Alraih AM; Ibraheem W
    PLoS One; 2023; 18(9):e0291256. PubMed ID: 37682937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Novel Inhibitors for ERα Target of Breast Cancer By In Silico Approach.
    Alagarsamy V; Sulthana MT; Narendhar B; Solomon VR; Gobinath M; Satishchandra A; Sangeetha D; Murugesan S
    Curr Comput Aided Drug Des; 2024 Jun; ():. PubMed ID: 38847264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.
    Bai C; Ren S; Wu S; Zhu M; Luo G; Xiang H
    Eur J Med Chem; 2021 Oct; 221():113543. PubMed ID: 34022716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of pseudobaptigenin as a novel polyphenol-based multi-target antagonist of different hormone receptors for breast cancer therapeutics.
    Ray S; Gupta S; Panda G; Chatterjee P; Das A; Patawri P; Hosseinzadeh P; Ray A; Banerjee S
    J Biomol Struct Dyn; 2024 Jul; 42(11):5502-5514. PubMed ID: 37409735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
    Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
    Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.